Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Inhibiting PIK3C3/VPS34 enhances anti-GD2 immunotherapy in neuroblastoma.
Journal: Autophagy
Published: August 20, 2026
Comment on: Implementing Health-Related Quality of Life Assessment in Pediatric Oncology: A Feasibility Study. The Clinical Impact and Implementation of a Child-Friendly Assessment Tool in Pediatric Oncology.
Journal: Pediatric blood & cancer
Published: June 12, 2026
Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth.
Journal: Oncogene
Published: November 19, 2025
CK2 inhibitor CX-4945 targets EWS-FLI1 protein abundance and shows anti-tumor activity in metastatic mouse models of Ewing Sarcoma.
Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025
Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy.
Journal: Journal of clinical medicine
Published: January 16, 2025
Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells.
Journal: Cancers
Published: September 23, 2024
Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.
Journal: Journal of pediatric hematology/oncology
Published: September 23, 2024
Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 27, 2024
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 26, 2023
Last Updated: 09/26/2026